Orion Pharma (DHA:ORIONPHARM) Short-Term Debt: BDT410 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DHA:ORIONPHARM Orion Pharma Ltd DHA:ORIONPHARM
72 GF Score
Price BDT29.90
GF Value BDT20.15
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Orion Pharma Short-Term Debt?

Orion Pharma DHA:ORIONPHARM -1.32% 72 Short-Term Debt is BDT410 Mil as of Mar. 2026. GuruFocus rates DHA:ORIONPHARM with a GF Score™ of 72/100 and a GF Value™ of BDT20.15 (Significantly Overvalued). The stock has 8 warning signs investors should review.

Orion Pharma's Short-Term Debt for the quarter that ended in Mar. 2026 was BDT410 Mil.

Orion Pharma's quarterly Short-Term Debt declined from Sep. 2025 (BDT458 Mil) to Dec. 2025 (BDT412 Mil) and declined from Dec. 2025 (BDT412 Mil) to Mar. 2026 (BDT410 Mil).

Orion Pharma's annual Short-Term Debt declined from Jun. 2023 (BDT1,038 Mil) to Jun. 2024 (BDT624 Mil) and declined from Jun. 2024 (BDT624 Mil) to Jun. 2025 (BDT494 Mil).

Orion Pharma Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Orion Pharma Short-Term Debt Related Terms

Orion Pharma Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Orion Pharma's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Orion Pharma Short-Term Debt Chart

Orion Pharma Annual Data
Trend Dec14 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 838.64 951.37 1,038.32 623.53 493.70

Orion Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 546.95 493.70 458.08 412.09 409.59
DHA:ORIONPHARM
72GF Score
Orion Pharma Ltd DHA:ORIONPHARM
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of BDT410 Mil mean?
Orion Pharma (DHA:ORIONPHARM) has a Short-Term Debt of BDT410 Mil as of Mar. 2026.
Is Orion Pharma's Short-Term Debt too high?
Orion Pharma's current Short-Term Debt is BDT410 Mil. Overall, Orion Pharma has a GF Score™ of 72/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Orion Pharma's Short-Term Debt compare to CEG and VST?
Orion Pharma's Short-Term Debt of BDT410 Mil can be compared against companies in the Utilities - Independent Power Producers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for an Utilities - Independent Power Producers company?
A good Short-Term Debt depends on the Utilities - Independent Power Producers industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Orion Pharma's current Short-Term Debt is BDT410 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orion Pharma stock overvalued right now?
Based on GuruFocus' analysis, Orion Pharma (DHA:ORIONPHARM) is currently considered Significantly Overvalued. The stock's GF Value™ is BDT20.15, compared to a current price of BDT29.90 — trading 48.4% above its estimated fair value. The current Short-Term Debt is BDT410 Mil. Orion Pharma's overall GF Score™ is 72/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Orion Pharma (DHA:ORIONPHARM), the current Short-Term Debt is BDT410 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Orion Pharma (DHA:ORIONPHARM) Overvalued in 2026?

Based on GuruFocus' analysis, Orion Pharma stock appears to be overvalued. The current stock price of BDT29.90 is trading 48.4% above its estimated GF Value™ of BDT20.15. GuruFocus considers Orion Pharma to be Significantly Overvalued.

Key valuation signals for DHA:ORIONPHARM:

  • Short-Term Debt: BDT410 Mil
  • GF Value™: BDT20.15 vs. price of BDT29.90 (48.4% above fair value)
  • GF Score™: 72/100 with 8 warning signs

No single metric tells the full story. See the DHA:ORIONPHARM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Orion Pharma Business Description

Address 153-154 Tejgaon Industrial Area, Orion House, Dhaka, BGD, 1208
Orion Pharma Ltd is a pharmaceutical company engaged in the creation and discovery, development, manufacturing, and marketing of pharmaceutical products, including vaccines and health-related consumer products. The company produces diversified dosage forms such as tablets, capsules, syrups, solutions, suspensions, powder for suspensions, creams, ointments, and injections under therapeutic categories including cardiovascular, antiulcerant, antiasthmatic, antihistamine, NSAIDs, antibiotic, antifungal, laxatives, anticancer, vitamins, and minerals. In addition, the company is involved in power generation activities and generates maximum revenue from pharmaceutical activities. The group principally carries out its business operations and markets its products in Bangladesh.
72GF Score

Get the complete analysis for DHA:ORIONPHARM

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

BDT29.90
Price
BDT20.15
GF Value